PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
- Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation
- Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022
- Biotech industry veteran Dr.
Carol Gallagherappointed to Board of Directors
“PMV continues to advance its ongoing PYNNACLE study evaluating PC14586, a first-in-class p53 Y220C reactivator, in patients with advanced solid tumors and plans the next update in the first half of 2023,” said
- Continued enrollment in the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors. Initial Phase 1 data presented at the 2022 ASCO annual meeting demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation.
- On track to initiate Phase 1b trial evaluating PC14586 in combination with KEYTRUDA in Q4 2022.
Carol Gallagher, Pharm.D. to the Board of Directors. Dr. Gallagherbrings 30 years of biotech leadership and expertise in drug development and commercialization.
Third Quarter 2022 Financial Results
- As of
September 30, 2022, PMV Pharma had $258.9 million in cash, cash equivalents, and marketable securities, compared to $314.1million at December 31, 2021. Net cash used in operations was $48.4 million for the nine months ended September 30, 2022, compared to $34.5 million for the nine months ended September 30, 2021.
- Net loss for the nine months ended
September 30, 2022, was $54.0 million compared to $39.5 million for the nine months ended September 30, 2021.
- Research and development (R&D) expenses were $37.0 million for the nine months ended September 30, 2022, compared to $24.3 million for the nine months ended
September 30, 2021. The increase in R&D expenses was primarily due to clinical expenses related to development of PC14586, the Company’s lead drug candidate.
- General and administrative (G&A) expenses were
$18.9 millionfor the nine months ended September 30, 2022, compared to $15.5 millionfor the nine months ended September 30, 2021. The increase in G&A expenses was primarily due to increased headcount expenses including stock-based compensation.
PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the crevice present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein structure and tumor-suppressing function. The
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for PC14586, including expectations regarding timing for its Phase 1 update for the PYNNACLE study and its Phase 1/2 combination trial of PC14586 and KEYTRUDA, as well as expectations regarding success of its current clinical trial for PC14586 and any future commercialization plans for the product candidate. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities and planned clinical trials, the Company’s ability to execute on its strategy and operate as an early clinical stage company, the potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2022, the Company’s Quarterly Report on Form 10-Q filed with the
Condensed Balance Sheets
|Cash and cash equivalents||$||99,850||$||172,467|
|Marketable securities, current||159,007||124,696|
|Prepaid expenses and other current assets||5,497||3,301|
|Total current assets||265,176||301,286|
|Property and equipment, net||9,966||3,090|
|Marketable securities, noncurrent||—||16,911|
|Liabilities and Stockholders’ Equity|
|Operating lease liabilities, current||394||403|
|Total current liabilities||11,656||12,219|
|Operating lease liabilities, noncurrent||12,135||10,790|
|Additional paid-in capital||483,916||476,363|
|Accumulated other comprehensive loss||(1,025||)||(78||)|
|Total stockholders’ equity||261,193||308,559|
|Total liabilities and stockholders’ equity||$||284,984||$||331,568|
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
|Three Months Ended
||Nine Months Ended
|Research and development||$||13,666||$||9,162||$||36,963||$||24,326|
|General and administrative||5,709||5,935||18,915||15,495|
|Total operating expenses||19,375||15,097||55,878||39,821|
|Loss from operations||(19,375||)||(15,097||)||(55,878||)||(39,821||)|
|Other income (expense):|
|Interest income, net||1,124||102||1,830||343|
|Other income (expense), net||13||3||67||14|
|Total other income (expense)||1,137||105||1,897||357|
|Loss before (benefit) provision for income taxes||(18,238||)||(14,992||)||(53,981||)||(39,464||)|
|(Benefit) provision for income taxes||(9||)||19||(9||)||23|
|Unrealized (loss) gain on available for sale investments, net of tax||(2||)||7||(947||)||14|
|Net loss per share -- basic and diluted||$||(0.40||)||$||(0.33||)||$||(1.18||)||$||(0.88||)|
|Weighted-average common shares outstanding||45,622,957||45,295,232||45,556,635||45,052,100|
Source: PMV Pharmaceuticals, Inc.